Blom, Dirk J.; Breedt, Johannes; Burgess, Lesley J.; Ebrahim, Iftikhar O.; Soma, Prashilla; Van der Walt, Eugene; Naidoo, Poobalan; Van Tonder, Alet; Raal, Frederick J.(Clinics Cardive, 2019-09-21)
BACKGROUND : Alirocumab reduces low-density lipoprotein
cholesterol (LDL-C) levels by up to 61%. The ODYSSEY
Open-Label Extension study investigated the effect of
alirocumab in patients with heterozygous familial ...
